Clinical Trial Update: Subcutaneous Infliximab After A Previous Intravenous Dose Optimization [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating subcutaneous infliximab after previous intravenous dose optimization for inflammatory bowel diseases, including Crohn's disease …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Inflammatory Bowel Disease
• Ulcerative Colitis

Drugs mentioned

• Remicade (infliximab)

Snippet

Sponsor: Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW | Conditions: Inflammatory Bowel Diseases, Crohn Disease | Phase 4 | Status: RECRUITING